Ocular Therapeutix, Inc. OCUL
6.02 USD +0.01 (+0.17%)
Regular-session close
6.02 0.00 0.00%
After hours · Nov 17, 4:01 PM ET
5.81 Day range 6.27
5.81 52-week range 16.44
- YTD
- -50.41%
- 1 year
- -49.37%
News
seekingalpha.com Ocular Therapeutix, Inc. (OCUL) Presents at UBS Global Biopharma Conference 2026 Transcript Ocular Therapeutix, Inc. (OCUL) Presents at UBS Global Biopharma Conference 2026 Transcriptbenzinga.com HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $28 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $28 price target.
seekingalpha.com Ocular: Maintaining 'Buy' On AXPAXLI NDA Submission Q4 2026 And DR Expansion Possibility Maintaining a "Buy" on Ocular Therapeutix, supported by FDA alignment on the AXPAXLI wet-AMD filing and opportunities to extend dosing and indications. The company expects Q4 2026 SOL-R 52-week…benzinga.com HC Wainwright & Co. Maintains Buy on Ocular Therapeutix, Raises Price Target to $28 HC Wainwright & Co. analyst Yi Chen maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $25 to $28.
benzinga.com Ocular Therapeutix Q3 2026 Earnings Call Transcript Ocular Therapeutix (NASDAQ:OCUL) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…benzinga.com Ocular Therapeutix Q3 EPS $(0.42) Misses $(0.36) Estimate, Sales $12.874M Miss $14.339M Estimate Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.36) by 16.67 percent. This is a 10.53 percent decrease over losses…
benzinga.com Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target Needham analyst Serge Belanger reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $18 price target.
